Biohaven scores CGRP OK for acute migraine — can the commercial team catch up with Allergan...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 28, 2020 at 12:02 AM.

  1. #1 cafead, Feb 28, 2020 at 12:02 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,024
    Likes Received:
    3
    via Seven years after spinning out of Yale, Biohaven has entered the ranks of commercial-stage biotechs.

    The FDA handed down an OK for its CGRP drug, rimegepant, as an acute treatment. Dubbed Nurtec, the orally dissolving pill will join Allergan’s (soon to be AbbVie’s) Ubrelvy and Lilly’s Reyvow on the market amid a new wave of migraine therapies reshaping the disease space.

    article source
     
    Quote

Reply to Thread